Linhai Percy Zhao, Ph.D.
Stock Analyst at Goldman Sachs
(n/a)
# 4,912
Out of 5,010 analysts
3
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Linhai Percy Zhao, Ph.D.
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HKG: 1672 Ascletis Pharma Inc. | Reiterated: Hold | $13.86 | $8.37 | +65.69% | 1 | Sep 2, 2026 | |
| HKG: 2595 GenFleet Therapeutics (Shanghai) Inc. | Initiated Coverage: Buy | $52.00 | $33.00 | +57.58% | 1 | Aug 30, 2026 | |
| HKG: 7630 IMPACT Therapeutics, Inc | Initiated Coverage: Hold | $37.60 | $14.07 | +167.24% | 1 | Jun 18, 2026 |
Ascletis Pharma Inc.
Sep 2, 2026
Reiterated: Hold
Price Target: $13.86
Current: $8.37
Upside: +65.69%
GenFleet Therapeutics (Shanghai) Inc.
Aug 30, 2026
Initiated Coverage: Buy
Price Target: $52.00
Current: $33.00
Upside: +57.58%
IMPACT Therapeutics, Inc
Jun 18, 2026
Initiated Coverage: Hold
Price Target: $37.60
Current: $14.07
Upside: +167.24%